Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis

European Journal of Nuclear Medicine

Volumn 28, Issue 6, 2001, Pages 704-710

  Wu, Hua ^a   Dimitrakopoulou Strauss, Antonia ^a   Heichel, Thomas O ^b   Lehner, Burkhard ^b   Bernd, Ludger ^b   Ewerbeck, Volker ^b   Burger, Cyrill ^c   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Bone neoplasms; Fluorine 18 fluordeoxy glucose; Glucose metabolism; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RADIOPHARMACEUTICALS; REFERENCE STANDARDS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035018230     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100511     Document Type: Article

References (34)

1. Wieler HJ. PET in der klinischen Onkologie. Darmstadt: Steinkopff; 1999:1-6.
2. Brock CS, Meikle SR, Price P. Does fluorine-18-fluordeoxy-glucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med 1997; 24:691-705.
3. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999; 40:1706-1715.
4. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000; 231:380-386.
5. Schulte M, Kotzerke J. Tumoren des Stütz- und Bewegungs- apparates. In: Wieler HJ, ed. PET in der klinischen Onkologie. Darmstadt: Steinkopff; 1999:300-314.
6. Kole AC, Nieweg OE, Hoekstra HJ, von Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluordeoxyglucose assessment of glucose metabolism in bone tumours. J Nucl Med 1998; 39: 810-815.
7. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology 1996; 200: 243-247.
8. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative (F-18) fluordeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
9. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508-1512.
10. Toorongian SA, Mulholland GK, Jewett DM, Bachelor MA, Kilbourn MR. Routine production of 2-deoxy-2(F-18)fluoro- D-glucose by direct nucleophilic exchange on a quaternary 4- amino-pyridinium resin. Nucl Med Biol 1990; 3:273-279.
11. Kontaxakis G, Tzanakos GS, Strauss LG. Characteristics of the local convergence behavior of the iterative ML-EM image reconstruction algorithms [abstract]. J Nucl Med 1997; 38:202.
12. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
13. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985; 5:584-590.
14. Ohtake T, Kosaka N, Watanabe T, et al. Non-invasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32:1432-1438.
15. 18F]fluoro-2-deoxy-D-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med 2000; 27:407-412.
16. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A JAVA environment for medical image data analysis: initial application for brain PET quantification. Med Inf (Lond) 1998; 23:207-214.
17. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997; 38:1818-1823.
18. Aoki J, Watanabe H, Shinozaki T, Tokunaga M, Inoue T, Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999; 23:603-8.
19. Warburg O. The metabolism of tumors. New York: Richard R Smith; 1991:129.
20. Hamkens W, Rösch F. FDG: Biochemisches Konzept und radiochemische Synthese. In: Wieler HJ, ed. PET in der klinischen Onkologie. Darmstadt: Steinkopff; 1999:59-66.
21. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radio pharmaceutical design: some factors responsible for the biodistribution of [F-18]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-1161.
22. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluoro-deoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257-261.
23. Eary JF, Mankoff DA. Tumor metabolic rate in sarcoma using FDG PET. J Nucl Med 1998; 39:250-254.
24. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fishman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
25. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34:1-6.
26. Keyes JW. SUV: standard uptake or silly useless value. J Nucl Med 1995; 36:1836-1839.
27. Priolo F, Cerase A. The current role of radiography in the assessment of skeletal tumors and tumor-like lesions. Eur J Radiol 1998; 27:S77-S85.
28. Campanacci M, Mercuri M, Gasbarrini A, Campanacci L. The value of imaging in the diagnosis and treatment of bone tumors. Eur J Radiol 1998; 27:S116-S122.
29. Shreve P, Grossman HB, Wahl RL. Initial assessment of FDG/PET detection of skeletal metastatic protest carcinoma [abstract]. J Nucl Med 1993; 34:223P.
30. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ. A PET study of FDG-18 uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
31. Choi JY, Lee KH, Kim SE, et al. Improved specificity of FDG-PET for differentiating bone tumors by FDG uptake pattern [abstract]. J Nucl Med 1999; 40:257P.
32. Schulte M, Brecht-Krauss D, Kotzerke J, Reske SN. Erlaubt die Positronen-Emissions-Tomographie mit FDG eine Dignitätsbeuteilung von primären Knochentumoren? [abstract]. Nuklearmedizin 1998; 37:A70.
33. Kubota R, Yamada S, Kubuta K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
34. Strauss LG. Fluorine-18-deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.